Zika Hearing Shows How Vaccine Timelines Are Outbreak-Dependent
This article was originally published in The Pink Sheet Daily
Executive Summary
NIAID appears on track to have Zika vaccine in widespread testing in late 2017, but development depends in part on the epidemic rate; additional funding is necessary to respond to the outbreak, NIAID director and CDC official testify at Senate and House hearings.
You may also be interested in...
Zika Vaccines Might Be Approved By 2020
Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.
Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.